Contrast-enhanced ultrasound detected portal vein thrombosis far better than CT in cases complicating hepatocellular carcinoma. While CT found only 68% of thrombi, contrast-enhanced ultrasound identified every one in the study. It also did a far better job of helping determine if they were malignant.
Contrast-enhanced ultrasound detected portal vein thrombosis far better than CT in cases complicating hepatocellular carcinoma. While CT found only 68% of thrombi, contrast-enhanced ultrasound identified every one in the study. It also did a far better job of helping determine if they were malignant.
Dr. Sandro Rossi and colleagues at the IRCCS Policlinico "S. Matteo" in Golgi, Italy, and Sunnybrook Health Science Centre in Toronto studied 50 patients diagnosed with hepatocellular carcinoma complicated by portal vein thrombosis. They published their study in European Radiology, which made it available online March 28.
In 37 cases, the thrombi involved segmental branches. The other 13 cases involved the main portal trunk. Each diagnosis was confirmed with biopsy, which also showed that 44 of the 50 thrombi were malignant.
Researchers performed CT scans and contrast-enhanced ultrasound exams the same week as the corresponding biopsies. Experienced readers under blinded conditions checked each exam for the presence of portal vein thrombosis and rated findings as either malignant or benign.
The researchers then compared these ratings with the biopsy results to determine accuracy. CT exams detected only 34 of the 50, or 68% of thrombi. Readers correctly characterized the malignancy of only 23 of these 34, or 68%.
Contrast-enhanced ultrasound detected all 50, or 100%, of thrombi. Readers correctly characterized the malignancy of 49 of the 50, or 98%.
The researchers concluded that contrast-enhanced ultrasound is significantly superior to CT when used in detecting and characterizing portal vein thrombosis as a complication of hepatocellular carcinoma. They recommend its use in the staging of these tumors.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.